ICUI
$132.06+5.10 (+4.02%)
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroCla...
Recent News
3 Profitable Stocks We Keep Off Our Radar
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
2 Healthcare Stocks with Exciting Potential and 1 We Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 5.7%, nearly mirrorring the S&P 500.
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
How ICU Medical’s 2025 Turnaround, FDA Clearance and 2026 Outlook At ICU Medical (ICUI) Has Changed Its Investment Story
ICU Medical, Inc. recently reported fourth-quarter 2025 results showing sales of US$540.7 million versus US$629.81 million a year earlier, narrowing its quarterly net loss to US$15.73 million while turning a small full-year 2025 net income of US$0.732 million on US$2.23 billion in sales. At the same time, the company resolved an FDA warning letter tied to its Smiths Medical business and issued 2026 GAAP net income guidance of US$26 million to US$44 million, signaling a cleaner regulatory...